- Home
- ALKS vs AXSM Comparison
ALKS vs AXSM Comparison
Compare ALKS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKS
- AXSM
- Stock Information
- Founded
- ALKS 1987
- AXSM 2012
- Country
- ALKS Ireland
- AXSM United States
- Employees
- ALKS N/A
- AXSM N/A
- Industry
- ALKS Biotechnology: Pharmaceutical Preparations
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- ALKS Health Care
- AXSM Health Care
- Exchange
- ALKS Nasdaq
- AXSM Nasdaq
- Market Cap
- ALKS 4.9B
- AXSM 5.9B
- IPO Year
- ALKS 1991
- AXSM 2015
- Fundamental
- Price
- ALKS $30.82
- AXSM $118.28
- Analyst Decision
- ALKS Strong Buy
- AXSM Strong Buy
- Analyst Count
- ALKS 14
- AXSM 19
- Target Price
- ALKS $41.43
- AXSM $174.26
- AVG Volume (30 Days)
- ALKS 1.9M
- AXSM 472.6K
- Earning Date
- ALKS 10-23-2025
- AXSM 11-03-2025
- Dividend Yield
- ALKS N/A
- AXSM N/A
- EPS Growth
- ALKS 21.99
- AXSM N/A
- EPS
- ALKS 2.08
- AXSM N/A
- Revenue
- ALKS $1,505,296,000.00
- AXSM $495,033,000.00
- Revenue This Year
- ALKS N/A
- AXSM $63.62
- Revenue Next Year
- ALKS $1.59
- AXSM $55.72
- P/E Ratio
- ALKS $14.89
- AXSM N/A
- Revenue Growth
- ALKS N/A
- AXSM 69.83
- 52 Week Low
- ALKS $25.17
- AXSM $75.56
- 52 Week High
- ALKS $36.45
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- ALKS 62.83
- AXSM 52.00
- Support Level
- ALKS $26.99
- AXSM $117.60
- Resistance Level
- ALKS $31.68
- AXSM $122.14
- Average True Range (ATR)
- ALKS 0.80
- AXSM 3.15
- MACD
- ALKS 0.36
- AXSM -0.28
- Stochastic Oscillator
- ALKS 81.88
- AXSM 36.43
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.